Mostrar el registro sencillo

dc.contributor.authorMonte, María J.
dc.contributor.authorAlonso Peña, Marta
dc.contributor.authorBriz, Óscar
dc.contributor.authorHerráez, Elisa
dc.contributor.authorBerasáin, Carmen
dc.contributor.authorArgemi, Josepmaría
dc.contributor.authorPrieto, Jesús
dc.contributor.authorMarín, José J. G.
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-11-25T15:19:43Z
dc.date.available2024-11-25T15:19:43Z
dc.date.issued2017
dc.identifier.issn0168-8278
dc.identifier.issn1600-0641
dc.identifier.otherSAF2013-40620-Res_ES
dc.identifier.otherSA015U13es_ES
dc.identifier.otherBIO/SA52/15es_ES
dc.identifier.urihttps://hdl.handle.net/10902/34505
dc.description.abstractBackground & Aims: Acyl-CoA oxidase (ACOX2) is involved in the shortening of C27 cholesterol derivatives to generate C24 bile acids. Inborn errors affecting the rest of peroxisomal enzymes involved in bile acid biosynthesis have been described. Here we aimed at investigating the case of an adolescent boy with persistent hypertransaminasemia of unknown origin and suspected dysfunction in bile acid metabolism. Methods: Serum and urine samples were taken from the patient, his sister and parents and underwent HPLC-MS/MS and HPLC-TOF analyses. Coding exons in genes of interest were amplified by high-fidelity PCR and sequenced. Wild-type or mutated (mutACOX2) variants were overexpressed in human hepatoblastoma HepG2 cells to determine ACOX2 enzymatic activity, expression and subcellular location. Results: The patient's serum and urine showed negligible amounts of C24 bile acids, but augmented levels of C27 intermediates, mainly tauroconjugated trihydroxycholestanoic acid (THCA). Genetic analysis of enzymes potentially involved revealed a homozygous missense mutation (c.673C>T; R225W) in ACOX2. His only sister was also homozygous for this mutation and exhibited similar alterations in bile acid profiles. Both parents were heterozygous and presented normal C24 and C27 bile acid levels. Immunofluorescence studies showed similar protein size and peroxisomal localization for both normal and mutated variants. THCA biotransformation into cholic acid was enhanced in cells overexpressing ACOX2, but not in those overexpressing mutACOX2. Both cell types showed similar sensitivity to oxidative stress caused by C24 bile acids. In contrast, THCA-induced oxidative stress and cell death were reduced by overexpressing ACOX2, but not mutACOX2. Conclusion: ACOX2 deficiency, a condition characterized by accumulation of toxic C27 bile acid intermediates, is a novel cause of isolated persistent hypertransaminasemia.es_ES
dc.description.sponsorshipFinancial support: this study was supported by the Institute of Health Carlos III, Spain (Grants FIS PI11/00337 and PI15/00179); Ministry of Science and Innovation, Spain (SAF2013-40620-R); “Junta de Castilla y León”, Spain (SA015U13 and BIO/SA52/15); “Fundacion Mutua Madrileña”, Spain (Call 2015); and “Fundacion Samuel Solórzano Barruso”, Spain (FS/10-2014). Marta Alonso-Peña is recipient of predoctoral fellowship from the Ministry of Education, Culture and Sport, Spain (BOE-A-2015-9456). Acknowledgments: the authors thank N. Skinner for revision of the English spelling, grammar and style of the manuscript and Virginia Villar for sample collection.es_ES
dc.format.extent30 p.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rights© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceJournal of Hepatology, 2017, 66(3), 581-588es_ES
dc.subject.otherBile acid metabolismes_ES
dc.subject.otherCholestatic liver diseaseses_ES
dc.subject.otherDrug-induced hepatotoxicityes_ES
dc.subject.otherGenetic disorderes_ES
dc.titleACOX2 deficiency: an inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemiaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1016/j.jhep.2016.11.005es_ES
dc.rights.accessRightsopenAccesses_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//SAF2013-40620-R/ES/IMPLICACION DE LOS GENES NR1H4, BIRC5 Y SLC22A1 EN LA QUIMIORRESISTENCIA Y QUIMIOSENSIBILIZACION DEL CANCER HEPATICO/es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/Junta de Castilla y León//SA015U13/ES/PAPEL DE LAS MUTACIONES DE LA PROTEÍNA DE CAPTACIÓN DE FÁRMACOS OCT1 EN LA REFRACTARIEDAD DEL CARCINOMA HEPATOCELULAR Y EL COLANGIOCARCINOMA AL TRATAMIENTO CON SORAFENIB/es_ES
dc.identifier.DOI10.1016/j.jhep.2016.11.005
dc.type.versionacceptedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 licenseExcepto si se señala otra cosa, la licencia del ítem se describe como © 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license